The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 23, 2018

Filed:

Apr. 25, 2012
Applicants:

Akira Myomoto, Kamakura, JP;

Satoko Kozono, Kamakura, JP;

Fumiaki Sato, Kyoto, JP;

Masakazu Toi, Kyoto, JP;

Takayuki Ueno, Kyoto, JP;

Zhipeng Wang, Kyoto, JP;

Gozoh Tsujimoto, Kyoto, JP;

Kazuharu Shimizu, Kyoto, JP;

Inventors:

Akira Myomoto, Kamakura, JP;

Satoko Kozono, Kamakura, JP;

Fumiaki Sato, Kyoto, JP;

Masakazu Toi, Kyoto, JP;

Takayuki Ueno, Kyoto, JP;

Zhipeng Wang, Kyoto, JP;

Gozoh Tsujimoto, Kyoto, JP;

Kazuharu Shimizu, Kyoto, JP;

Assignees:

TORAY INDUSTRIES, INC., Tokyo, JP;

KYOTO UNIVERSITY, Kyoto, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2006.01); A61K 39/395 (2006.01); C07K 16/32 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 39/39558 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01);
Abstract

This invention relates to a composition and a method for prediction of a response to Trastuzumab therapy in a breast cancer patient, and more specifically, a composition, a kit, a DNA chip, and a method for predicting a response to Trastuzumab therapy by using polynucleotides each comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 9, 11 to 19, and 21 to 23 in the Sequence Listing or a nucleotide sequence derived therefrom by substitution of u with t, mutants thereof, derivatives thereof, or fragments thereof comprising at least 16 continuous nucleotides, or a polynucleotide comprising a complementary sequence thereof, and using an increase or decrease in Her2 protein expression level as an indicator.


Find Patent Forward Citations

Loading…